These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 3808131

  • 1. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R, Schneevoigt K.
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract] [Full Text] [Related]

  • 2. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I, Serbănescu A, Tudorache B.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982 Nov; 27(4):261-70. PubMed ID: 6222452
    [No Abstract] [Full Text] [Related]

  • 3. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M, Kempster PA.
    Clin Exp Neurol; 1994 Nov; 31():38-42. PubMed ID: 7586663
    [Abstract] [Full Text] [Related]

  • 4. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
    Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O.
    Mov Disord; 1997 May; 12(3):277-84. PubMed ID: 9159719
    [Abstract] [Full Text] [Related]

  • 5. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 6. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD.
    Adv Neurol; 1996 Aug; 69():3-11. PubMed ID: 8615142
    [No Abstract] [Full Text] [Related]

  • 7. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A, Dambrosia JM, Chase TN.
    Adv Neurol; 1993 Aug; 60():698-702. PubMed ID: 8420213
    [No Abstract] [Full Text] [Related]

  • 8. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
    Goberman AM, Coelho C.
    NeuroRehabilitation; 2002 Aug; 17(3):237-46. PubMed ID: 12237505
    [Abstract] [Full Text] [Related]

  • 9. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [Abstract] [Full Text] [Related]

  • 10. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agrò E.
    Neurology; 2007 May 01; 68(18):1455-9. PubMed ID: 17470746
    [Abstract] [Full Text] [Related]

  • 11. Acoustic analysis of parkinsonian speech II: L-Dopa related fluctuations and methodological issues.
    Goberman AM, Coelho C.
    NeuroRehabilitation; 2002 May 01; 17(3):247-54. PubMed ID: 12237506
    [Abstract] [Full Text] [Related]

  • 12. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A, Grau-Veciana JM.
    Med Clin (Barc); 1985 Jun 15; 85(3):88-91. PubMed ID: 4021630
    [No Abstract] [Full Text] [Related]

  • 13. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
    Pantelatos A, Fornadi F.
    Adv Neurol; 1993 Jun 15; 60():690-7. PubMed ID: 8420212
    [Abstract] [Full Text] [Related]

  • 14. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H, Rousseaux M, Mazingue A, Warot P.
    LARC Med; 1983 Jun 15; 3(7):514-6. PubMed ID: 6645742
    [No Abstract] [Full Text] [Related]

  • 15. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E, Tárczy M.
    Adv Neurol; 1993 Jun 15; 60():672-5. PubMed ID: 8420208
    [No Abstract] [Full Text] [Related]

  • 16. [Results of L-dopa treatment in parkinsonism (author's transl)].
    Kolasa M, Reichowa J, Bieniowa A.
    Przegl Lek; 1976 Jun 15; 33(3):407-10. PubMed ID: 1273335
    [No Abstract] [Full Text] [Related]

  • 17. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan 15; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 18. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
    Arch Neurol; 2006 Feb 15; 63(2):205-9. PubMed ID: 16476808
    [Abstract] [Full Text] [Related]

  • 19. [Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
    Bonduelle M, Degos CF.
    Int J Neurol; 1979 Feb 15; 13(1-4):255-61. PubMed ID: 263185
    [No Abstract] [Full Text] [Related]

  • 20. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ, Evtushenko SK, Dukhovnaia MA.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Feb 15; 84(9):1334-8. PubMed ID: 6506979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.